Parkinson’s Disease: Seeing Disease Modification

Duygu Tosun-Turgut, PhD

Professor of Radiology and Biomedical Imaging, UCSF and Founding Director of Medical Imaging Informatics and AI

Dr. Duygu Tosun-Turgut’s research focuses on neurodegenerative diseases and psychiatric disorders and application of advanced imaging technology for discovery of multi-modal biomarkers to detect the progression of neurodegenerative pathologies before they cause irreversible damage to the brain. She aims to develop validated biomarkers of neurodegeneration for early diagnosis, initiation of prevention strategies, monitoring of efficacy, and clinical trial enrichment.

David Russell, MD, PhD

Sr. Scientific Director, Perceptive Imaging

Dr. Russell is a neurologist specializing in movement disorders, dementias, and other neurodegenerative disorders. He has been a member of the Yale Movement Disorders Clinic for 30+ years and is an asst. clinical professor at the Yale University School of Medicine. Dr. Russell’s research & clinical interests include investigations of the mechanisms and prevention of neuronal dysfunction and development of early molecular and biomarker indicators of loss or alteration of specific brain systems.

Elif Sikoglu, PhD

Assoc. Prof., Dept. of Molecular & Medical Pharmacology; Director, Theranostics, UCLA

Dr. Sikoglu brings 20+ years of imaging experience in advanced MRI applications and operationalization of imaging biomarkers in CNS clinical trials. She has been the scientific lead for 200+ clinical trials across neurological / psychiatric indications incl. Alzheimer’s & Parkinson’s disease, multiple sclerosis, stroke, mood disorders and rare diseases. She has played a critical role in the development and implementation of acquisition guidelines, read review criteria, and quantitative analysis.